Skip to content

Evaluation of the effect of Pay-it-forward on improving HPV vaccine uptake among key groups in Chengdu, China: A randomized controlled trial

The effectiveness of pay-it-forward in addressing HPV vaccine delay and increasing uptake among 15–18-year-old adolescent girls compared to user-paid vaccination: two-arm randomized controlled trial in China

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055542
Enrollment
Unknown
Registered
2022-01-11
Start date
2022-01-11
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

“Pay-it-forward”:1) an educational pamphlet about cervical cancer, HPV vaccination, and differences in common types of HPV vaccines
2) information about the pay-it-forward vaccination program, including its purpose, the opportunity to receive postcard messages and subsidized HPV vaccination, and the opportunity to voluntarily dona
Standard-of-care:1) An educational pamphlet about cervical cancer, HPV vaccination, and differences in common types of HPV vaccines (Same as in pay-it-forward arm)
2) Inform the HPV Vaccine Service and its price in the Community Health Center, which is available at your own expense.

Sponsors

Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria are females: 1) aged 15–18years; 2) living in the communities served by the selected community health centers; 3) with no HPV vaccination history, 4) with no prior allergies to vaccines; and 5) have a legal guardian who consents to participate the study.

Exclusion criteria

Exclusion criteria: Exclusion criteria are females: 1) aged below 15 or above 18years; 2) not living in the neighborhood served by the community health centers; 3) received HPV vaccine(s); 4) ineligible to receive a vaccine based on clinical evaluation from a physician; or 5) a legal guardian refuses to consent to participate.

Design outcomes

Primary

MeasureTime frame
First-dose HPV vaccine uptake;

Secondary

MeasureTime frame
Donation rate and donations in pay-if-forward arm;Vaccine delay;Vaccine confidence;Economic evaluation;

Countries

China

Contacts

Public ContactLi Jing

Sichuan University

lijingwcph@scu.edu.cn+86 132 4022 5540

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026